The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
| Autor: | Aviral Singh, Nisaar Korowlay, Lucille Heslop, Masha Maharaj, Trisha Govender, Mike Sathekge, Partha Choudhary |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy Radiosensitizer Cumulative dose business.industry medicine.medical_treatment Low dose Castrate-resistant prostate cancer Case Report urologic and male genital diseases medicine.disease 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine Docetaxel 030220 oncology & carcinogenesis Internal medicine medicine Radiology Nuclear Medicine and imaging Re challenge business medicine.drug |
| Zdroj: | Nucl Med Mol Imaging |
| ISSN: | 1869-3482 1869-3474 |
| DOI: | 10.1007/s13139-021-00696-5 |
| Popis: | Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 ((177)Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably safe with attractive clinical responses. Re-challenge (177)Lu-PSMA therapy in early responders has been shown to be safe and effective. We report the use of low-dose Taxol-based chemotherapy (modified dose 25 mg/m(2) weekly × 6 weeks) as a radiosensitizer with re-challenge (177)Lu-PSMA therapy (4 cycles). In a period of 3 years, the patient underwent a total of 8 cycles of (177)Lu-PSMA with a cumulative dose of 51.8 GBq. All therapies were uneventful and well tolerated. There was a good response to re-challenge (177)Lu-PSMA therapy and low-dose docetaxel (Taxol-(177)Lu-PSMA) with no recorded tumour resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink